Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Development and Validation of a Gd-IgA1 Guided Precision Therapy System for Targeted Therapeutic Strategies of IgA Nephropathy： An Open-label, Random Controlled Trial

NCT07822100 is registered in ClinicalTrials.gov with Hong Zhang as lead sponsor.

NCT NCT07822100
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07822100 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Development and Validation of a Gd-IgA1 Guided Precision Therapy System for Targeted Therapeutic Strategies of IgA Nephropathy： An Open-label, Random Controlled Trial
Lead sponsor
Hong Zhang
Phase
Not applicable
Overall status
Recruiting
Start date
August 24, 2026
Completion date
February 29, 2028
Enrollment
374 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

henoch schönlein purpura nephritis, iga nephropathy (igan)